Merck to assume full responsibility for Erbitux in Japan from Bristol Myers-Squibb

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Merck and Bristol-Myers Squibb have agreed to transfer full responsibility for the promotion of Erbitux (cetuximab) to Merck in Japan as of May 1.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

When Judith O. Hopkins started medical school in 1974, she had to sign a contract promising to not get pregnant.  This was not the most egregious form of sexism she would face in her career. Seeking a residency in emergency medicine in 1977, she was told point blank that she would not be considered. “I...

Login